RxDoctor Payments DataLook up a doctor →

Courtney Iser, MD

Neurology · Oklahoma City, OKNPI 1144758079

Payments from drug & device makers

$56,273in general payments, 2019–2025

Across 741 payments — averaging $75.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$47K
  • UCB, Inc.$1K
  • Pfizer$912
  • Lundbeck LLC$723
  • Teva Pharmaceuticals USA, Inc.$672
  • SK Life Science, Inc.$540
  • plus $5K from 46 others

What the payments were for

  • Speaking & faculty fees$42,73876%
  • Travel & lodging$1,8313%
  • Food & beverage$11,70421%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,273 in reported general payments places this provider in the 80th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$221,782
Medicare patients
212
Services billed
24,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate50$85,585
UbrelvyUbrogepant63$83,827
Aimovig AutoinjectorErenumab-Aooe73$55,744
Emgality PenGalcanezumab-Gnlm61$48,599
Ajovy AutoinjectorFremanezumab-Vfrm39$31,755
QuliptaAtogepant14$13,922
Emgality SyringeGalcanezumab-Gnlm15$12,626
Memantine Hcl117$4,384
Rivastigmine15$3,832
Lacosamide68$3,488
Levetiracetam134$3,178
Lamotrigine ErLamotrigine13$1,770
Gabapentin113$1,382
Oxcarbazepine20$1,306
RizatriptanRizatriptan Benzoate68$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$47,112$97,74977 claims
PfizerNurtec Odt$912$85,58550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →